J. Fleming

发表

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer

C. Ponting, A. Heger, D. Sims, 2014, BMC Cancer.

Molecular Mechanisms of Cancer Prevention by Selenium Compounds

P. Harrison, J. Fleming, A. Ghose, 2001, Nutrition and cancer.

Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-β: but p53 mutations are not necessarily required

E. Parkinson, K. Gordon, P. Harrison, 2003, Oncogene.

Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated protein kinase and Fas pathways.

P. Harrison, J. Fleming, K. El-Bayoumy, 2001, Cancer research.

Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis.

P. Harrison, J. Lanfear, J. Fleming, 1993, Carcinogenesis.

Selenium and signal transduction: roads to cell death and anti-tumour activity.

P. Harrison, J. Fleming, A. Ghose, 2001, BioFactors.

The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium?

P. Harrison, J. Lanfear, J. Fleming, 1994, Carcinogenesis.

Cis and trans control of erythroid cell-specific gene expression during erythropoiesis

M. Plumb, J. O'prey, P. Harrison, 1988, Journal of Cell Science.

The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases.

A. Aitken, B. Thiele, J. O'prey, 1989, Gene.

Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression

O. Sansom, L. Rushworth, D. Sumpton, 2022, Cancer research.

Cloning of a rabbit erythroid-cell-specific lipoxygenase mRNA.

B. Thiele, J. O'prey, P. Harrison, 1987, Gene.

Analysis of Erythroid Cell-Specific Gene Expression

B. Thiele, P. Harrison, J. Chester, 1987 .

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

Andreas Heger, Chris P. Ponting, Owen J. Sansom, 2014, European urology.

Analysis of red blood cell differentiation.

J. O'prey, P. Harrison, E. Black, 1982, Advances in experimental medicine and biology.

Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells

K. Ryan, J. O'prey, H. Leung, 2010, Cell Death and Disease.

The promoter structure and complete sequence of the gene encoding the rabbit erythroid cell-specific 15-lipoxygenase.

B. Thiele, J. O'prey, P. Harrison, 1989, Gene.

SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis

J. Norman, O. Sansom, J. Edwards, 2012, EMBO molecular medicine.

Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.

O. Sansom, J. Edwards, I. Ahmad, 2013, The Journal of clinical investigation.

Sprouty 2 , PTEN , and PP 2 A interact to regulate prostate cancer progression

O. Sansom, J. Edwards, I. Ahmad, 2013 .

Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1

F. Hamdy, A. Blomme, O. Sansom, 2018, EMBO molecular medicine.

Sprouty 2 loss-induced IL 6 drives castration-resistant prostate cancer through scavenger receptor B 1

F. Hamdy, A. Blomme, O. Sansom, 2018 .

Divergent routes to oral cancer.

Gabriela Kalna, Pawel Herzyk, D. Higham, 2006, Cancer research.

Telomere dysfunction is related to the intrinsic radio-resistance of human oral cancer cells.

E. K. Parkinson, K. Gordon, J. Fleming, 2008, Oral oncology.

Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.

E. Parkinson, P. Harrison, J. Fleming, 2002, Cancer research.

Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells.

J. O'prey, P. Harrison, J. Fleming, 2003, Biochemical pharmacology.

BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration

Matthew P. Neilson, C. Robson, K. Blyth, 2019, Oncogene.

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer

J. Cuzick, D. Berney, P. Scardino, 2013, British Journal of Cancer.

Regulation of erythroid cell-specific gene expression during erythropoiesis.

M. Plumb, J. O'prey, P. Harrison, 1988, The British journal of cancer. Supplement.

A monoclonal antibody against erythrocyte spectrin reacts with both alpha- and beta-subunits and detects spectrin-like molecules in non-erythroid cells.

P. Harrison, J. Fleming, K. Kasturi, 1983, Experimental cell research.

Does androgen‐ablation therapy (AAT) associated autophagy have a pro‐survival effect in LNCaP human prostate cancer cells?

C. Robson, K. Ryan, J. O'prey, 2013, BJU international.

Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive to S-Trityl-l-Cysteine–Mediated Eg5 Inhibition

C. Robson, H. Leung, F. Kozielski, 2010, Molecular Cancer Therapeutics.

Cyclocreatine suppresses prostate tumorigenesis through dual effects on SAM and creatine metabolism

O. Sansom, L. Rushworth, D. Sumpton, 2021, bioRxiv.

ERK5 signalling in prostate cancer promotes an invasive phenotype

I. Ahmad, H. Leung, E. Keller, 2011, British Journal of Cancer.

Regulation of erythroid-specific gene expression.

B. Thiele, M. Plumb, J. O'prey, 1990, Biomedica biochimica acta.

Chemopreventive and growth inhibitory effects of selenium.

P. Harrison, J. Lanfear, J. Fleming, 1997, Biomedical and environmental sciences : BES.

Correction: BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration

Matthew P. Neilson, C. Robson, K. Blyth, 2019, Oncogene.

Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive to S-Trityl-l-Cysteine–Mediated Eg5 Inhibition

C. Robson, H. Leung, F. Kozielski, 2010, Molecular Cancer Therapeutics.